A Compound Mitigates Cancer Pain and Chemotherapy-Induced Neuropathic Pain by Dually Targeting nNOS-PSD-95 Interaction and GABAA Receptor
Authors:
- 1 October 2021
- journal article
- research article
- Published by Elsevier in Neurotherapeutics
- Vol. 18 (4) , 2436-2448
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- The Economic Costs of Pain in the United StatesThe Journal of Pain, 2012
- Treatment of cerebral ischemia by disrupting ischemia-induced interaction of nNOS with PSD-95Nature Medicine, 2010
- Central Sensitization: A Generator of Pain Hypersensitivity by Central Neural PlasticityThe Journal of Pain, 2009
- Disruption of nNOS‐PSD95 protein–protein interaction inhibits acute thermal hyperalgesia and chronic mechanical allodynia in rodentsBritish Journal of Pharmacology, 2009
- Persistent Inflammation Induces GluR2 Internalization via NMDA Receptor-Triggered PKC Activation in Dorsal Horn NeuronsJournal of Neuroscience, 2009
- Chemotherapy‐induced neuropathyJournal of the Peripheral Nervous System, 2008
- Cancer pain and its impact on diagnosis, survival and quality of lifeNature Reviews Neuroscience, 2006
- Spinal glial activation in a new rat model of bone cancer pain produced by prostate cancer cell inoculation of the tibiaPain, 2005
- NMDA receptors as targets for drug action in neuropathic painEuropean Journal of Pharmacology, 2001
- Malignant bone pain: pathophysiology and treatmentPain, 1997